Management of recurrent or metastatic thyroid cancer

Recently, vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitors (TKIs) have become available for the treatment of recurrent or metastatic thyroid cancer. However, a number of clinical challenges that impact the use of VEGFR-targeted TKI in daily clinical practice ha...

Descripción completa

Detalles Bibliográficos
Autor principal: Tahara, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922569/
https://www.ncbi.nlm.nih.gov/pubmed/29713501
http://dx.doi.org/10.1136/esmoopen-2018-000359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922569/
https://www.ncbi.nlm.nih.gov/pubmed/29713501
http://dx.doi.org/10.1136/esmoopen-2018-000359

Ejemplares similares